Study Finds IVIG No More Effective Than Tocilizumab for Severe COVID-19, Shows Higher Adverse Event Rate and Cost.

A recent study examined the effectiveness of intravenous immunoglobulin (IVIG) treatment compared to tocilizumab for patients with severe COVID-19. The research indicates that IVIG did not demonstrate significant benefits over tocilizumab in treating severe cases of the virus. Researchers also observed that the use of IVIG was associated with a higher incidence of adverse events and increased costs. The study compared the outcomes of patients receiving IVIG with those receiving tocilizumab, a medication already in use for severe COVID-19. The findings revealed that IVIG treatment did not result in a statistically significant improvement in patient outcomes when compared to tocilizumab. Furthermore, the study documented a greater number of adverse events among patients treated with IVIG. Researchers also reported the financial costs associated with IVIG therapy exceeded those related to tocilizumab treatment.

Newsflash | Powered by GeneOnline AI
Date: April 24, 2025

Author

Mark Chiang